Blocking the survival of the nastiest by HSP90 inhibition

被引：9
作者：
Workman, Paul [1 ]
Clarke, Paul A. [1 ]
Al-Lazikani, Bissan [1 ]
机构：
[1] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, London SW3 6JB, England
来源：
ONCOTARGET | 2016年 / 7卷 / 04期
关键词：
HSP90; CLONAL EVOLUTION; CANCER; RESISTANCE; THERAPY; MODELS;
D O I：
10.18632/oncotarget.6971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance - knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.
引用
收藏
页码：3658 / 3661
页数：4
相关论文
共 50 条
  • [11] Geldanamycin and its derivatives as Hsp90 inhibitors
    Gorska, Magdalena
    Popowska, Urszula
    Sielicka-Dudzin, Alicja
    Kuban-Jankowska, Alicja
    Sawczuk, Wojciech
    Knap, Narcyz
    Cicero, Giuseppe
    Bucchieri, Fabio
    Wozniak, Michal
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2012, 17 : 2269 - 2277
  • [12] A comparison of Hsp90α and Hsp90β interactions with cochaperones and substrates
    Taherian, Aliakbar
    Krone, Patrick H.
    Ovsenek, Nick
    BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 2008, 86 (01): : 37 - 45
  • [13] Macrocyclic Inhibitors of Hsp90
    Johnson, Victoria A.
    Singh, Erinprit K.
    Nazarova, Lidia A.
    Alexander, Leslie D.
    McAlpine, Shelli R.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (14) : 1380 - 1402
  • [14] Hsp90: A Drug Target?
    Jeffrey M. Holzbeierlein
    Andrew Windsperger
    George Vielhauer
    Current Oncology Reports, 2010, 12 : 95 - 101
  • [15] Hsp90: A Drug Target?
    Holzbeierlein, Jeffrey M.
    Windsperger, Andrew
    Vielhauer, George
    CURRENT ONCOLOGY REPORTS, 2010, 12 (02) : 95 - 101
  • [16] NOVEL MECHANISMS OF SENSITIVITY AND ACQUIRED RESISTANCE TO HSP90 INHIBITION BY GANETESPIB
    Busacca, Sara
    Pringle, Howard
    Law, Edward
    O'Regan, Laura
    Fry, Andrew M.
    Matchett, Kyle
    Reichert, Vienna
    El-Hariry, Iman
    El-Tanani, Mohamed
    Fennell, Dean A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S328 - S329
  • [17] Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 Inhibition
    Poole, Candace J.
    Zheng, Wenli
    Lee, Haesung
    Young, Danielle
    Lodh, Atul
    Chadli, Ahmed
    van Riggelen, Jan
    CANCERS, 2018, 10 (11):
  • [18] Hsp90 inhibition sensitizes DLBCL cells to cisplatin
    Schmidt, Linnea
    Issa, Issa Ismail
    Haraldsdottir, Hulda
    Hald, Jonas Laugard
    Schmitz, Alexander
    Due, Hanne
    Dybkaer, Karen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 431 - 440
  • [19] Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS
    Nethisinghe, Suran
    Abeti, Rosella
    Kesavan, Maheswaran
    Wigley, W. Christian
    Giunti, Paola
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [20] Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors
    Kang, Junghee
    Kamal, Adeela
    Burrows, Francis J.
    Evers, B. Mark
    Chung, Dai H.
    ANTICANCER RESEARCH, 2006, 26 (3A) : 1903 - 1908
12345